HCID 58529647, compound → HCID 58529454, compound

Participants

Reaction Steps

In a manner similar to the procedure described for step 7 of the preparation of Example 330 and using 2-benzyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazole and tert-butyl 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate as starting material, 411 mg (95.6%) of the desired product was isolated. 1H NMR (400 MHz, CD2Cl2) δ 8.06 (s, 1H), 8.94 (s, 1H), 8.92 (d, 1 H), 7.49 (d, 1H), 7.37-7.45 (m, 5 H), 6.59 (s, 1H), 4.49 (s, 2 H), 4.25 (m, 2 H), 3.42 (m, 1H), 2.94 (m, 2H), 2.11 (m, 2H), 1.76-1.64 (m, 2 H), 1.48 (s, 9H); LC-MS m/z [M+H]+541.2, RT 3.37 min.

Provenance & Evidence